The report provides a detailed analysis essential for establishing a Repaglinide production plant. It encompasses all critical aspects necessary for Repaglinide production, including the cost of Repaglinide production, Repaglinide plant cost, Repaglinide production costs, and the overall Repaglinide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Repaglinide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Repaglinide is primarily used as an oral antihyperglycemic agent in the pharmaceutical industry for the treatment of type 2 diabetes mellitus (non-insulin-dependent diabetes). Its industrial application is focused on improving glycaemic control by stimulating insulin release from pancreatic β cells, thus lowering postprandial blood glucose levels. Additionally, significant research also focuses on enhancing its bioavailability and delivery, such as through nanoparticle-based transdermal systems.
The market demand for Repaglinide is driven by the global rise in the cases of type 2 diabetes, driven by lifestyle changes and ageing populations, which fuels demand for glucose-lowering drugs like Repaglinide. Advantages of Repaglinide, such as rapid onset of action and short half-life, make it effective for controlling postprandial blood glucose, supporting its preference in diabetes management.
A growing geriatric population, more prone to type 2 diabetes, increases demand for effective treatments like Repaglinide. Increased awareness about diabetes management and early diagnosis globally also propel the market demand. The entry and availability of generic formulations boost affordability and accessibility, which further contribute to the market growth. Advancements in pharmaceutical formulation technologies and newer drug delivery systems improve efficacy and patient compliance. However, competition from alternative diabetes drugs like metformin, sulfonylureas, and GLP-1 receptor agonists, and side effect concerns such as hypoglycaemia that can affect adherence, impact industrial repaglinide procurement.
Raw Material for Repaglinide Production
According to the Repaglinide production plant project report, the raw material for Repaglinide production includes 2-(3-ethoxy-4-(ethoxycarbonyl)phenyl)acetic acid.
Production Process of Repaglinide
The extensive Repaglinide production cost report consists of the following major industrial production process:
- Production via a two-step process: The production process of Repaglinide occurs through a two-step industrial process beginning with the conversion of 2-(3-ethoxy-4-(ethoxycarbonyl)phenyl)acetic acid to its acid chloride intermediate using an acid chloride reagent. This intermediate then undergoes coupling with (S)-3-methyl-1-(2-(piperidin-1-yl)phenyl)butan-1-amine in the presence of a base and dicyclohexylcarbodiimide (DCC) as the coupling agent to form an amide bond. In the final step, the resulting product is subjected to alkaline hydrolysis to remove the ethoxycarbonyl protecting group, followed by pH adjustment to yield Repaglinide.
Properties of Repaglinide
Repaglinide is a white to off-white crystalline powder with a molecular formula of C27H36N2O4 and a molecular weight of 452.6 g/mol. Its melting point ranges from 126–130 degree Celsius, and it is nearly odourless. Repaglinide shows amphoteric behaviour due to the presence of both weakly acidic and basic groups. It is soluble in DMSO (~34 mg/mL) and has moderate water solubility (about 90 mg/L at 25 degree Celsius), but overall exhibits poor aqueous solubility typical of many oral hypoglycaemic agents. The compound has an estimated pKa of 4.19 and a topological polar surface area of 78.87 Ų, with 2 hydrogen bond donors and 11 rotatable bonds. Repaglinide tends to be stable when stored between 2–8 degree Celsius. It is classified as a benzoic acid derivative and functions pharmacologically as a short-acting potassium channel blocker, stimulating insulin release for type 2 diabetes therapy.
